Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | G6PD | P11413 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.35 |
| ▸ | PAK1 | Q13153 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | PI4KA | P42356 | 1/20 | 0.31 |
| ▸ | XDH | P47989 | 1/20 | 0.31 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.31 |
| ▸ | PI4K2B | Q8TCG2 | 1/20 | 0.31 |
| ▸ | PI4K2A | Q9BTU6 | 1/20 | 0.31 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL240979 | 0.80 | TP53 (0.52) | G6PDTP53HSD17B10PAK1NOTUM | |
| SCHEMBL754882 | 0.76 | ALDH1A1 (0.39) | G6PDTP53HSD17B10PAK1NOTUM | |
| SCHEMBL2115552 | 0.76 | PAK1 (0.40) | G6PDTP53HSD17B10PAK1NOTUM | |
| SCHEMBL1725582 | 0.73 | PAK1 (0.62) | TP53HSD17B10PAK1LMNAXDH | |
| SCHEMBL2118555 | 0.73 | PAK1 (0.48) | TP53HSD17B10PAK1NOTUMLMNA | |
| SCHEMBL8826229 | 0.72 | PAK1 (0.61) | PAK1LMNAXDHHTT | |
| SCHEMBL10925300 | 0.72 | PAK1 (0.61) | PAK1LMNAXDHHTT | |
| SCHEMBL735449 | 0.72 | NOTUM (0.60) | NOTUMLMNAHTT | |
| SCHEMBL21316653 | 0.71 | TP53 (0.36) | G6PDTP53HSD17B10PAK1NOTUM | |
| Adenine SCHEMBL8110 | 0.70 | PI4KA (0.48) | LMNADRD3PI4KAXDHLRRK2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2346878-B1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA SA (BE) | 2014-10-01 | — | — | EP | disclosed |
| US-8653272-B2 | Fused pyridine derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2014-02-18 | — | — | US | disclosed |
| US-8399483-B2 | Quinoxaline and quinoline derivatives as kinase inhibitors | UCB PHARMA S.A. (BE) | 2013-03-19 | — | — | US | disclosed |
| US-20110201630-A1 | Fused Pyridine Derivatives as Kinase Inhibitors | UCB PHARMA S.A. (BE) | 2011-08-18 | — | — | US | disclosed |
| EP-2346878-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma, S.A. (BE) | 2011-07-27 | — | — | EP | disclosed |
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA, S.A. (BE) | 2011-05-05 | — | — | US | disclosed |
| WO-2010061180-A1 | QUINOLINE DERIVATIVES AS P13 KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-06-03 | — | — | WO | disclosed |
| WO-2010046639-A1 | FUSED PYRIDINE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2010-04-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105508-A1 | QUINOXALINE AND QUINOLINE DERIVATIVES AS KINASE INHIBITORS | PDXK, PDPK1, PIKFYVE | G6PD 601/4885TP53 2194/4885HSD17B10 3399/4885 |
| US-20110201630-A1 | Fused Pyridine Derivatives as Kinase Inhibitors | MAP2K2, MAP4K2, MAP3K6 | G6PD 1218/4885TP53 1839/4885HSD17B10 3458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.